BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29108296)

  • 1. Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin
    Cui W; Fan W; Zhang Q; Wen J; Huang Y; Yang J; Li J; Wang Y
    Oncotarget; 2017 Oct; 8(45):79165-79174. PubMed ID: 29108296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma.
    Shao W; Li C; Tang J; Song J; Li Z; Sun J; Xu Y; Zheng Z; Cao J; Zhang L
    Cancer Manag Res; 2019; 11():9863-9869. PubMed ID: 31819623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
    Zhao C; Fan L; Qi F; Ou S; Yu L; Yi X; Ni B; Zheng Z; Lu J; Zhang C; Chen C; Lu X; Cheng L; Hu T; Ma Y
    Anticancer Drugs; 2016 Aug; 27(7):689-94. PubMed ID: 27145327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis.
    Wei N; Zhang B; Wang Y; He XH; Xu LC; Li GD; Wang YH; Wang GZ; Huang HZ; Li WT
    Clin Transl Oncol; 2019 Apr; 21(4):443-450. PubMed ID: 30306400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma.
    Liu B; Zhu X; Gao S; Guo J; Wang X; Cao G; Zhu L; Liu P; Xu H; Chen H; Zhang X; Liu S; Kou F
    J Interv Med; 2019 May; 2(2):91-96. PubMed ID: 34805879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization.
    Wu Y; Zheng S; Zhang Z; Chen G; Chen X; Zheng T; Guo X; Chen H; Wang M; Xie X; Zhang B
    Medicina (Kaunas); 2022 Sep; 58(10):. PubMed ID: 36295504
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma.
    Zhang W; Chen L; Cao Y; Sun B; Ren Y; Sun T; Zheng C
    Cancer Manag Res; 2021; 13():5391-5402. PubMed ID: 34262347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial.
    Zhu HD; Li X; Ji JS; Huang M; Shao GL; Lu J; Zhao XY; Li HL; Yang ZQ; Tu JF; Zhou JM; Zeng CH; Teng GJ
    Eur Radiol; 2022 Nov; 32(11):7335-7343. PubMed ID: 35776182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases.
    Feng AW; Guo JH; Gao S; Kou FX; Liu SX; Liu P; Chen H; Wang XD; Xu HF; Cao G; Zhu X
    Front Oncol; 2022; 12():913017. PubMed ID: 36212504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
    Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
    Bi Y; Shi X; Ren J; Yi M; Han X; Song M
    BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
    Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
    World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
    Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
    Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion of oxaliplatin plus raltitrexed in unresectable hepatocellular carcinoma with or without portal vein tumour thrombosis.
    Chen S; Yu W; Zhang K; Liu W; Wang X; Chen C
    Gastroenterol Rep (Oxf); 2022; 10():goac016. PubMed ID: 35582475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin
    Liao R; Zhang XD; Li GZ; Qin KL; Yan X
    J Gastrointest Oncol; 2020 Aug; 11(4):747-759. PubMed ID: 32953158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.
    Ghiringhelli F; Vincent J; Bengrine L; Borg C; Jouve JL; Loffroy R; Guiu B; Blanc J; Bertaut A
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2357-2363. PubMed ID: 31273511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.